Review: Immunomodulators for all patients with inflammatory bowel disease?

Abstract

Recent insight into the pathogenesis of Crohn’s disease (CD) and ulcerative colitis (UC) have led to the development of new treatment options, with a progressive shift to more evidence-based strategies based on sound pathophysiological rationales. A better understanding of inflammatory bowel disease (IBD) pathophysiology has progressively resulted in a more frequent use of immunomodulators. We review the recommended or suggested use of conventional immunomodulators such as azathioprine, 6-mercaptopurine, methotrexate in the treatment of IBD. Moreover, an effort is made to explore some critical areas in which early and more diffuse use of these agents may be advocated.

Keywords

azathioprine Crohn’s disease immunomodulators inflammatory bowel disease (IBD)treatment ulcerative colitis

References

Alfadhli, A.A.F. , McDonald, J.W.D. and Feagan, B.G. ( 2004) Methotrexate for induction of remission in refractory Crohn’s disease. Cochrane Database of Systematic Reviews 4: CD003459. DOI: 10.1002/ 14651858.CD003459.pub2.

Ardizzone, S. and Bianchi Porro, G. ( 2002) Inflammatory bowel disease: new insights into pathogenesis and therapy. J Intern Med 252: 475-496.

Ardizzone, S. , Bollani, S. , Manzionna, G. , Imbesi, V. , Colombo, E. and Bianchi Porro, G. ( 2003) Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn’s disease: a randomized, investigator-blind study. Dig Liver Dis 35: 619-627.

Ardizzone, S. , Maconi, G. , Russo, A. , Imbesi, V. , Colombo, E. and Bianchi Porro, G. ( 2006) Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut 55: 47-53.

Ardizzone, S. , Maconi, G. , Sampietro, G.M. , Russo, A. , Radice, E. , Colombo, E. et al. (2004) Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn’s disease. Gastroenterology 127: 730-740.

Baert, F. , Noman, M. , Vermeire, S. , Assche, G. , D’Haens, G. , Carbonz, A. et al. (2003) Influence of immunogenicity on the longterm efficacy of infliximab in Crohn’s disease. N Engl J Med 348: 601-608.

Beaugerie, L. , Carrat, F. , Bouvier, A.-M. , Brousse, N. , Carbonnel, F. , Colombel, J.-F. et al. (2008) Excess risk of lymphoproliferative disorders (LPD) in inflammatory bowel disease (IBD): interim results of the CESAME cohort . Gastroenterology 134(Suppl. 1): A116-A177.

Beaugerie, L. , Seksik, P. and Carrat, F. ( 2009) Thiopurine therapy is associated with a three-fold decrease in the incidence of advanced colorectal neoplasia in IBD patients with longstanding extensive colitis: the CESAME prospective data. J Crohn’s Colitis 3: S5 (Abstract).

Beaugerie, L. , Seksik, P. , Nion-Larmurie, I. , Gendre, J.P. and Cosnes, J. ( 2006) Predictors of Crohn’s disease. Gastroenterology 130: 650-656.

10.

Cassinotti, A. and Travis, S. (2009) Incidence and clinical significance of immunogenicity to infliximab in Crohn’s disease: a critical systematic review. Inflamm Bowel Dis 15: 1264-1275.

11.

Chande, N. , MacDonald, J.K. and McDonald, J.W.D. ( 2007) Methotrexate for induction of remission in ulcerative colitis. Cochrane Database of Systematic Reviews 4: CD006618. DOI: 10.1002/ 14651858.CD006618.pub2.

12.

Colombel, J.F. , Sandborn, W.J. , Rutgeerts, P. , Enns, R. , Hanauer, S.B. , Panaccione, R. et al. (2007) Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology 132: 52-65.

13.

D’Haens, G. , Geboes, K. , Ponette, E. , Penninckx, F. and Rutgeerts, P. ( 1997) Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn’s disease. Gastroenterology 112: 1475-1481.

14.

D’Haens, G. , Geboes, K. and Rutgeerts, P. ( 1999) Endoscopic and histologic healing of Crohn’s (ileo-) colitis with azathioprine. Gastrointest Endosc 50: 667-671.

15.

D’Haens, G.R. , Vermeire, S. , Van Assche, G. , Noman, M. , Aerden, I. , Van Olmen, G. et al. (2008) Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn’s disease: a controlled randomized trial. Gastroenterology 135: 1123-1129.

16.

Dubinsky, M.C. ( 2004) Azathioprine, 6-mercaptopurine in inflammatory bowel disease: pharmacology, efficacy, and safety. Clin Gastroenterol Hepatol 2: 731-743.

17.

Etchevers, M.J. , Aceituno, M. and Sans, M. ( 2008) Are we giving azathioprine too late? The case for early immunomodulation in inflammatory bowel disease. World J Gastroenterol 14: 5512-5518.

18.

Feagan, B.G. , Fedorak, R.N. , Irvine, E.J. , Wild, G. , Sutherland, L. , Steinhart, A.H. et al. (2000) A comparison of methotrexate with placebo for the maintenance of remission in Crohn’s disease. N Engl J Med 342: 1627-1632.

19.

Feagan, B.G. , McDonald, J.W.D. , Panaccione, R. , Enns, R. , Bernstein, C.N. , Ponich, T. et al. (2008) A randomized trial of methotrexate in combination with infliximab for the treatment of Crohn’s disease [abstract]. Gut 57(SII): A66.

20.

Feagan, B.G. , Rochon, J. , Fedorak, R.N. , Irvine, E.J. , Wild, G. , Sutherland, L. et al. (1995) Methotrexate for the treatment of Crohn’s disease. N Engl J Med 332: 292-297.

21.

Fraser, A.G. , Orchard, T.R. and Jewell, D.P. ( 2002) The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 50: 485-489.

22.

Froslie, K.F. , Jahnsen, J. , Moum, B.A. and Vatn, M.H. and the IBSEN Group (2007) Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 133: 412-422.

23.

Gisbert, J.P. , Linares, P.M. , Mcnicholl, A.G. , Maté, J. and Gomollòn, F. (2009) Meta-analysis: the efficacy of azathioprine and mercaptopurine in ulcerative colitis. Aliment Pharmacol Ther 30: 126-137.

24.

Hanauer, S.B. , Korelitz, B.I. , Rutgeerts, P. , Peppercorn, M.A. , Thisted, R.A. , Cohen, R.D. et al. (2004) Postoperative maintenance of Crohn’s disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology 127: 723-729.

25.

Hanauer, S.B. , Sandborn, W.J. , Rutgeerts, P. , Fedorak, R.N. , Lukas, M. , MacIntosh, D. et al. (2006) Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology 130: 323-333.

26.

Herfarth, H. , Tjaden, C. , Lukas, M. , Obermeier, F. , Dilger, K. , Muller, R. et al. (2006) Adverse events in clinical trials with azathioprine and mesalamine for prevention of postoperative recurrence of Crohn’s disease. Gut 55: 1525-1526.

27.

Kandiel, A. , Fraser, A.G. , Korelitz, B.I. , Bresinger, C. and Lewis, J.D. ( 2005) Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 54: 1121-1125.

28.

Korzenik, J.R. and Podolsky, D.K. ( 2006) Evolving knowledge and therapy of inflammatory bowel disease . Nat Rev Drug Discov 5: 197-209.

29.

Langholz, E. , Munkholm, P. , Davidsen, M. and Binder, V. ( 1994) Course of ulcerative colitis: analyis of changes in disease activity over years. Gastroenterology 107: 3-11.

30.

Lewis, J. , Schwartz, S. and Lichtenstein, G.R. ( 2000) Azathioprine for maintenance of remission in Crohn’s disease: benefits outweigh the risk of lymphoma. Gastroenterology 118: 1018-1024.

31.

Lichtenstein, G.R. , Abreu, M.T. , Cohen, R. and Tremaine, W. ( 2006) American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 130: 940-987.

32.

Mackey, A.C. , Green, L. , Liang, L.C. , Dinndorf, P. and Avigan, M. ( 2007) Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 44: 265-267.

33.

Markowitz, J. , Grancher, K. , Kohn, N. , Lesser, M. and Daum, F. ( 2000) A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn’s disease. Gastroenterology 119: 895-902.

34.

Masunaga, Y. , Ohno, K. , Ogawa, R. , Hashiguchi, M. , Echizen, H. and Ogata, H. ( 2007) Meta-analysis of risk of malignancy with immunosuppressive drugs in inflammatory bowel disease. Ann Pharmacother 41: 21-28.

35.

Modigliani, R. , Mary, J.Y. , Simon, J.F. , Cortot, A. , Soule, J.C. , Genere, J.P. et al. (1990) Clinical, biological, and endoscopic picture of attacks of Crohn’s disease. Evolution on prednisolone. Groupe d’Etude Therapeutique des Affections Inflammatoires Digestives. Gastroenterology 98: 811-818.

36.

Munkholm, P. , Langholz, E. , Davidsen, M. and Binder, V. ( 1995) Disease activity in a regional cohort of Crohn’s disease patients. Scand J Gastroenterol 30: 699-706.

37.

Olaison, G. , Sjodahl, R. and Tagesson, C. ( 1990) Glucocorticoid treatment in ileal Crohn’s disease: relief of symptoms but not of endoscopically viewed inflammation. Gut 31: 325-328.

38.

Oren, R. , Arber, N. , Odes, S. , Moshkowitz, M. , Keter, D. , Pomeranz, I. et al. (1996) Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial. Gastroenterology 110: 1416-1421.

39.

Pearson, D.C. , May, G.R. , Fick, G.H. and Sutherland, L.R. ( 1995) Azathiorpine and 6-mercaptopurine in Crohn’s disease. A meta-analysis. Ann Intern Med 123: 132-142.

40.

Peyrin-Biroulet, L. , Deltenre, P. , Ardizzone, S. , D’Haens, G. , Hanauer, S.B. , Herfarth, H. et al. (2009) Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn’s disease: a meta-analysis. Am J Gastroenterol 104: 2089-2096.

41.

Prefontaine, E. , Sutherland, L.R. , MacDonald, J.K. and Cepoiu, M. ( 2009) Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn’s disease. Cochrane Database of Systematic Reviews 1: CD000067. DOI:10.1002/14651858. CD000067.pub2.

42.

Punati, J. , Markowitz, J. , Lerer, T. , Hyams, J. , Kugathasan, S. , Griffiths, A. et al. (2008) Effect of early immunomodulator use in moderate to severe pediatric Crohn’s disease. Inflamm Bowel Dis 14: 949-954.

43.

Rutgeerts, P. , Feagan, B.G. , Lichtenstein, G.R. , Mayer, L.F. , Schreiber, S. , Colombel, J.F. et al. (2004) Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease. Gastroenterology 126: 402-413.

44.

Rutter, M. , Saunders, B. , Wilkinson, K. , Rumbles, S. , Schofield, G. , Kamm, M. et al. (2004) Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 126: 451-459.

45.

Salliott, C. and van der Heijde, D. (2009) Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis 68: 1100-1104.

46.

Sandborn, W.J. , Hanauer, S.B. , Rutgeerts, P. , Fedorak, R.N. , Lukas, M. , MacIntosh, D.G. et al. (2007) Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial. Gut 56: 1232-1239.

47.

Sandborn, W.J. , Rutgeerts, P. , Reinisch, W. , Kornbluth, A. , Lichtiger, S. , D’Haens, G. et al. (2008) SONIC: a randomized, doubleblind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn’s disease naive to immunomodulators and biologic therapy. Am J Gastroenterology 103: S436 [abstract].

48.

Sandborn, W.J. , Sutherland, L.R. , Pearson, D. , May, G. , Modigliani, R. and Prantera, C. ( 2000) Azathioprine or 6-mercaptopurine for induction of remission in Crohn’s disease. Cochrane Database of Systematic Reviews 3: CD000545. DOI: 10.1002/ 14651858.CD000545.

49.

Siegel, C.A. , Marden, S.M. , Persing, S.M. , Larson, R.J. and Sands, B.E. (2009) Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn’s disease: a meta-analysis. Clin Gastroenterol Hepatol 7: 874-881.

50.

Timmer, A. , McDonald, J.W.D. and MacDonald, J.K. ( 2007) Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database of Systematic Reviews 1: CD000478. DOI: 10.1002/14651858.CD000478.pub2.

51.

Travis, S.P. , Stange, E.F. , Lémann, M. , Oresland, T. , Chowers, Y. , Forbes, A. et al. (2006) European evidence based consensus on the diagnosis and management of Crohn’s disease: current management. Gut 55(Suppl. I): i16-i35.

52.

Travis, S.P.L. , Stange, E.F. , Lémann, M. , Oresland, T. , Bemelman, W.A. , Chowers, Y. et al. (2008) European evidence-based consensus on the management of ulcerative colitis: current management. J Crohn’s Colitis 2: 24-62.

53.

Van Assche, G. , Magdelaine-Beuzelin, C. , D’Haens, G. , Baert, F. , Noman, M. , Vermeire, S. et al. (2008) Withdrawal of immunosuppression in Crohn’s disease treated with scheduled infliximab maintenance: a randomized trial . Gastroenterology 134: 1861-1868.

54.

Velayos, F.S. , Terdiman, J.P. and Walsh, J.M. ( 2005) Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies . Am J Gastroenterol 100: 1345-1353.

55.

Vermeire, S. , Noman, M. , Van Assche, G. , Baert, F. , D’Haens, G. , Rutgeerts, P. et al. (2007) Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn’s disease. Gut 56: 1226-1231.